CLEVELAND, Jan. 12, 2022 /PRNewswire/ -- GenomOncology
announced today that GenomOncology (GO) Pathology Workbench has
been selected by Labcorp's OmniSeq to support the analysis and
reporting of OmniSeq INSIGHT℠, a comprehensive genomic and immune
profiling test for solid tumors.
OmniSeq INSIGHT combines genomic and immune profiling to
comprehensively characterize a patient's tumor to identify
potential treatment and clinical trial options. OmniSeq INSIGHT
examines the full coding region of 523 genes by next generation
sequencing for mutations, copy number alterations, fusions
microsatellite instability (MSI), tumor mutation burden (TMB), and
expression of 64 immune genes in the tumor microenvironment. The
test also includes PD-L1 by immunohistochemistry.
"Our partnership with GenomOncology has advanced our ability to
efficiently classify variants, match therapies and identify trials
located within 200 miles of the patient's home," says Shengle Zhang, MD, Laboratory Director of
OmniSeq. "This highly customized laboratory information system
supports OmniSeq's competitive turnaround time of matched precision
medicine options to ordering clinicians for their cancer
patients."
To streamline variant review, interpretation, and case
reporting, OmniSeq implemented the highly customized GO Pathology
Workbench. Central to the GO Pathology Workbench's function is a
proprietary, algorithmically-driven database of evidence and
guideline-based therapeutic options and clinical trials. The
results are displayed in the comprehensive OmniSeq INSIGHT test
report.
"The adaptability and versatility of the GO Pathology Workbench
enabled us to efficiently customize the workbench to accommodate
the unique features of the OmniSeq INSIGHT test. By providing the
knowledge and evidence needed for effective variant interpretation,
GO Pathology Workbench provides a tool to support OmniSeq INSIGHT's
swift turnaround time," said Matt
Stachowiak, PhD, Director of Product Management at
GenomOncology.
In June 2021, Labcorp (NYSE: LH),
a leading global life sciences company, acquired OmniSeq. OmniSeq
INSIGHT is available to U.S.-based clinicians exclusively through
Labcorp, and across Canada through
Dynacare, a Labcorp company. The test is also available to global
biopharmaceutical companies exclusively through Labcorp Drug
Development. For more information about OmniSeq INSIGHT, visit
oncology.labcorp.com/omniseq.
About GenomOncology
GenomOncology provides the
healthcare community with data-driven insights to improve cancer
care. GenomOncology strengthens your precision oncology program by
transforming valuable, but unusable data, into actionable oncology
treatment options and strategic insights. GenomOncology's Precision
Oncology Platform (POP) powers its comprehensive set of end-to-end
software solutions that enhance decision support. POP combines both
proprietary content and public and licensed data sets with your
internal patient data to provide you the information necessary to
improve patient outcomes. Learn more at www.genomoncology.com.
Media Contact
Alysia
Kaplan, Director of Marketing
GenomOncology, LLC
(440) 617-6087
alysia@genomoncology.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/genomoncology-pathology-workbench-to-support-omniseq-insight-a-genomic-and-immune-profiling-test-that-identifies-potential-treatment-and-clinical-trial-options-for-solid-tumors-301458486.html
SOURCE GenomOncology